Adverse events observed during infliximab therapy – a national multicenter study
T Molnár, P Miheller, G Horváth, A Grenda, Z Szepes, F Nagy, Z Tulassay, J Lonovics · Zeitschrift für Gastroenterologie · 2006 · Heft 06
Bibliografische Angaben
Zusammenfassung
Biological therapy is widely used in the treatment of severe Crohn's disease (CD), but the profile of the adverse events of these new agents has not yet been really recognized. Aim: A retrospective assessment of the frequency and severity of the side-effects observed during treatment of CD with infliximab, a chimerical TNF-alpha blocker. Patients and methods: 129 patients (diagnosis: 124 CD, 5 ulcerative colitis (UC); female/male ratio: 79/50; mean age: 36, 17–72 years) at three Hungarian centers were treated with infliximab. The total number of infusions during the period from March 2000 to January 2006 was 424…
